Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316516 | 0.73 | GAA (0.39) | CXCR3GAADPP4 | |
| SCHEMBL15025803 | 0.73 | SIGMAR1 (0.33) | — | |
| SCHEMBL6314584 | 0.72 | GAA (0.38) | CXCR3GAADPP4 | |
| SCHEMBL6315051 | 0.71 | GAA (0.43) | GAADPP4 | |
| SCHEMBL654309 | 0.69 | EPHX2 (0.40) | CXCR3GAAEPHX2 | |
| SCHEMBL30184983 | 0.69 | EPHX2 (0.40) | CXCR3GAAEPHX2 | |
| SCHEMBL24853669 | 0.66 | EPHX2 (0.41) | CXCR3GAAEPHX2 | |
| Dexborneol SCHEMBL56713 | 0.66 | EPHX2 (0.41) | GAAEPHX2 | |
| Dexborneol SCHEMBL20576252 | 0.66 | EPHX2 (0.41) | GAAEPHX2 | |
| Borneol SCHEMBL20576251 | 0.66 | EPHX2 (0.41) | GAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110111068-A1 | Inhibitors of cognitive decline | CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS FOUNDATION, CHANNEL ISLANDS ALZHEIMER'S INSTITUTE | 2011-05-12 | — | — | US | disclosed |
| US-20110111068-A1 | Inhibitors of cognitive decline | CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS FOUNDATION, CHANNEL ISLANDS ALZHEIMER'S INSTITUTE | 2011-05-12 | — | — | US | disclosed |
| US-7723377-B2 | Inhibitors of cognitive decline | COGNITION THERAPEUTICS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723377-B2 | Inhibitors of cognitive decline | COGNITION THERAPEUTICS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080193574-A1 | Inhibitors Of Cognitive Decline | COGNITION THERAPEUTICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193574-A1 | Inhibitors Of Cognitive Decline | COGNITION THERAPEUTICS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111068-A1 | Inhibitors of cognitive decline | NAA50, NOS1, NOS2 | CXCR3 4652/4885GAA 338/4885DPP4 3113/4885 |
| US-20080193574-A1 | Inhibitors Of Cognitive Decline | NAA50, NOS1, NOS2 | CXCR3 4652/4885GAA 338/4885DPP4 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.